Caribou Biosciences Limited Use Label License: Research Use Only

Notice End Users: This product is purchased from or otherwise provided by The Jackson Laboratory subject to a “Limited Use Label License” conveying to the end-user  (“End User”) of the product a limited, non-transferable right to use the product, solely as provided to End User, together with (i) progeny or derivatives of the product generated by the End User (including, but not limited to, cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including, but not limited to, cells) (collectively, the product, as provided, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the End User.

The End User cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes or reproductive cells; and/or (h) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). Notwithstanding the foregoing, End User may transfer Material to a third party under a contractual obligation to perform research for the sole benefit of the End User, or to a third party that is a nonprofit performing collaborative research with the End User; provided however that any such transfer of Material to a third party is accompanied by this Limited Use Label License.

It is the End User’s responsibility to use the Material in accordance with all applicable laws and regulations.

For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing.

 

Exhibit A: Licensed Patent Rights

Modified Cascade Ribonucleoproteins and Uses Thereof

 

Country

Application number/

Patent number

Filing date/

Grant date

Status

 

 

 

 

US

14/240,735

02/24/2014

Abandoned

US

14/326,099

07/08/2014

Abandoned

US

14/997,467

01/15/2016

Pending

US

14/997,474

01/15/2016

Pending

AU

2012360975

12/21/2012

Pending

BR

112014016228-0

12/21/2012

Pending

CA

2,862,018

12/21/2012

Pending

CN

201280071058.4

12/21/2012

Abandoned

CN

201610081216.4

12/21/2012

Pending

DE

212012000234.0

212012000234.0

12/21/2012

08/07/2014 (exp. 12/21/2022)

Granted

EP

12812999.6

12/21/2012

Abandoned

EP

16169431.0

12/21/2012

Pending

GB

1411878.0

2512246

12/21/2012

07/20/2016 (exp. 12/21/2032)

Granted

IL

233399

12/21/2012

Pending

IN

5937/DELNP/2014

12/21/2012

Pending

JP

2014-549450

12/21/2012

Pending

KR

2014-7021336

12/21/2012

Pending

MX

MX/a/2014/007910

12/21/2012

Pending

RU

2014127702

12/21/2012

Pending

SG

11201403713Q

12/21/2012

Pending

TH

1401003836

12/21/2012

Pending

WO

PCT/EP2012/076674

12/21/2012

National phase

GB

1122458.1

12/30/2011

Withdrawn

 


 

Compositions and Methods of Nucleic Acid-Targeting Nucleic Acids

 

Country

Application number/

Patent number

Filing date/

Grant date

Status

 

 

 

 

US

14/206,319

03/12/2014

Pending

US

14/416,338

US 9,260,752

01/22/2015

02/16/2016 (exp. 03/12/2034)

Granted

US

14/749,594

06/24/2015

Pending

US

14/749,599

06/24/2015

Pending

US

14/751,055

US 9,410,198

06/25/2015

08/09/2016 (exp. 03/12/2034)

Granted

US

14/751,058

06/25/2015

Pending

US

14/751,070

06/25/2015

Pending

US

14/751,088

06/25/2015

Pending

US

14/977,514

12/21/2015

Pending

US

15/159,619

05/19/2016

Pending

US

15/159,776

05/19/2016

Pending

US

15/202,518

07/05/2016

Pending

AU

2014235794

03/12/2014

Pending

AU

2015101418

2015101418

03/12/2014

10/29/2015 (exp. 03/12/2022)

Granted

BR

112015022061-4

03/12/2014

Pending

CA

2,905,432

03/12/2014

Pending

CN

201480028062.1

03/12/2014

Pending

EP

14771135.2

03/12/2014

Pending

GB

1517172.1

03/12/2014

Pending

HK

16100993.9

03/12/2014

Pending

IL

241563

03/12/2014

Pending

IN

5749/CHENP/2015

03/12/2014

Pending

JP

2016-501357

03/12/2014

Pending

KR

2015-7028606

03/12/2014

Pending

MX

MX/a/2015/013057

03/12/2014

Pending

NZ

712727

03/12/2014

Pending

RU

2015140276

03/12/2014

Pending

SG

11201507378U

03/12/2014

Pending

ZA

2015/07006

03/12/2014

Pending

WO

PCT/US2014/023828

03/12/2014

National phase

US

61/781,598

03/14/2013

Expired

US

61/818,382

05/01/2013

Expired

US

61/818,386

05/01/2013

Expired

US

61/822,002

05/10/2013

Expired

US

61/832,690

06/07/2013

Expired

US

61/845,714

07/12/2013

Expired

US

61/858,767

07/26/2013

Expired

US

61/859,661

07/29/2013

Expired

US

61/865,743

08/14/2013

Expired

US

61/883,804

09/27/2013

Expired

US

61/899,712

11/04/2013

Expired

US

61/900,311

11/05/2013

Expired

US

61/902,723

11/11/2013

Expired

US

61/903,232

11/12/2013

Expired

US

61/906,211

11/19/2013

Expired

US

61/906,335

11/19/2013

Expired

US

61/907,216

11/21/2013

Expired

US

61/907,777

11/22/2013

Expired

 


 

RNA Modification to Engineer Cas9 Activity

 

Country

Application number/

Patent number

Filing date/

Grant date

Status

 

 

 

 

US

14/791,195

07/02/2015

Pending

US

14/791,200

07/02/2015

Pending

WO

PCT/2015/037546

06/24/2015

Pending

US

62/017,113

06/25/2014

Expired

US

62/065,515

10/17/2014

Expired

US

62/088,277

12/05/2014

Expired

 


 

 

Methods for Increasing Cas9-Mediated Engineering Efficiency

 

Country

Application number/

Patent number

Filing date/

Grant date

Status

 

 

 

 

US

14/836,753

08/26/2015

Pending

WO

PCT/US2015/047046

08/26/2015

Pending

US

62/042,358

08/27/2014

Expired

US

62/047,495

09/08/2014

Expired

 


 

RNA-Directed DNA Cleavage by the Cas9-crRNA Complex

(Owner: Vilnius University)

Amended and Restated Collaboration and License Agreement, by and between Pioneer Hi-Bred International, Inc. and Caribou Biosciences, Inc., dated July 13, 2015

 

Country

Application number/

Patent number

Filing date/

Grant date

Status

 

 

 

 

US

14/385,241

09/15/2014

Pending

US

14/385,857

09/17/2014

Pending

US

14/683,443

04/10/2015

Pending

US

14/743,764

06/18/2015

Pending

BR

112014023353-5

03/20/2013

Pending

CA

2,867,849

03/20/2013

Pending

CN

201380023255.3

03/20/2013

Pending

EA

201491728

03/20/2013

Pending

EP

13715080.1

03/20/2013

Pending

HK

2015107124

03/20/2013

Pending

IN

7846/DELNP/2014

03/20/2013

Pending

JP

2015-5011880

03/20/2013

Pending

MX

MX/a/2014/011279

03/20/2013

Pending

ZA

2014/06897

2014/06897

03/20/2013

12/23/2015 (exp. 03/20/2033)

Granted

WO

PCT/LT2013/000006

03/15/2013

National phase

WO

PCT/US2013/033106

03/20/2013

National phase

US

61/613,373

03/20/2012

Expired

US

61/625,420

04/17/2012

Expired

 


 

Methods and Compositions for RNA-Directed Target DNA Modification

and for RNA-Directed Modulation of Transcription

(Owners: The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier)

Exclusive License Agreement, by and among Caribou Biosciences, Inc., University of Vienna, and The Regents of the University of California, dated April 16, 2013

 

Country

Application number/

Patent number

Filing date/

Grant date

Status

 

 

 

 

US

13/842,859

03/15/2013

Interference No. 106,048 pending

US

14/403,475

11/24/2014

Abandoned

US

14/685,502

04/13/2015

Pending

US

14/685,504

04/13/2015

Pending

US

14/685,513

04/13/2015

Abandoned

US

14/685,514

04/13/2015

Abandoned

US

14/685,516

04/13/2015

Abandoned

US

14/942,782

11/16/2015

Pending

US

15/090,511

04/04/2016

Pending

US

15/138,604

04/26/2016

Pending

AU

2013266968

03/15/2013

Pending

BR

1120140299441-0

03/15/2013

Pending

CA

2,872,241

03/15/2013

Pending

CN

201380038920.6

03/15/2013

Pending

DE

202013012240

202013012240

03/15/2013

02/02/2016 (exp. 03/31/2023)

Granted

DE

202013012241

202013012241

03/15/2013

01/18/2016 (exp. 03/31/2023)

Granted

DE

202013012242

202013012242

03/15/2013

02/02/2016 (exp. 03/31/2023)

Granted

EA

201401319

03/15/2013

Pending

EP

13793997.1

03/15/2013

Pending

GB

1420270.9

GB2518764

03/15/2013

03/02/2016 (exp. 03/15/2033)

Granted

GB

1601071.2

03/15/2013

Pending

HK (EP)

15104473.1

03/15/2013

Pending

HK (CN)

15112610.8

03/15/2013

Pending

HK (GB)

15106335.4

03/15/2013

Pending

IL

235461

03/15/2013

Pending

IN

2995/KOLNP/2014

03/15/2013

Pending

JP

2015-514015

03/15/2013

Pending

KR

2014-7036096

03/15/2013

Pending

MX

MX/a/2014/014477

03/15/2013

Pending

SG

11201407702X

03/15/2013

Pending

ZA

2014/07881

03/15/2013

Pending

WO

PCT/US2013/032589

03/15/2013

National phase

US

61/652,086

05/25/2012

Expired

US

61/716,256

10/19/2012

Expired

US

61/757,640

01/28/2013

Expired

US

61/765,576

02/15/2013

Expired